David Meininger Email & Phone Number

United States

Shanghai, CN

Seattle, WA, US

Mountain View, CA, US

Gyre is built for biopharma consulting, investment and new company formation.

Seattle, Washington, US

Seattle, Washington, US

Promote Trianni's best-in-class human antibody discovery platform. Source technology licensing opportunities and lead associated transactions. Facilitate academic collaborations and proliferation of Trianni technology.

Rahway, New Jersey, US

Member of Bay Area BD&L group. Responsibilities include in- and out-licensing of therapeutic assets, initiating and maintaining collaborations with external partners and advising the Merck Research Venture Fund team on selected investment opportunities.

Rahway, New Jersey, US

Head of Department of Protein Sciences. Responsible for lead generation and early characterization efforts at Merck supporting indications addressed by Merck's Disease Area franchises. Member of Biologics Review and Licensing Committee and Ambrx Joint Steering Committee.

Rahway, New Jersey, US

Head of Department responsible for all large molecule lead discovery and early characterization efforts at Merck. Projects pursued span the full spectrum of indications addressed by Merck's seven Disease Area Franchises.

Ingelheim Am Rhein, Rhineland-Palatinate, DE

Head of Biberach NBE Unit. Departmental focus on discovery, design and early development of New Biological Entities. Indications span those across Cardiometabolic, Respiratory, and CNS therapeutic areas.

Thousand Oaks, CA, US

Protein Biochemistry group leader supervising ten direct and skip-level reports. Group focus on homology modeling/construct design, purification and characterization of mammalian, insect and microbial cell culture-derived antibodies, antigens, enzymes and other research proteins in support of multiple Amgen oncology and inflammation therapeutic area.

Thousand Oaks, CA, US

Protein Purification group member supervising two direct reports while working full-time at the bench. Responsibility for purification and characterization of mammalian cell culture-derived antibodies, antigens, enzymes and other research proteins in support of multiple Amgen therapeutic area projects. Core team member on key ESA research project with.

US

Protein expression and purification sub-group leader supervising two to three direct reports. Design and assistance in production of oncology drug-target and other protein expression vectors. Supervision and assistance in production of protein from baculovirus-infected insect cells, yeast, and E. coli for co-crystallization with small-molecule drug leads.

(Gryphon was a start-up engaged in chemical synthesis of protein therapeutics including epo and others. Its $100mm deal with Amgen terminated shortly after my departure).Supervision of two direct reports in synthesis and chemical ligation of peptides and polymers into novel, long-acting protein therapeutics homologues. Optimization of synthesis of organic.

Supervision of two direct reports in gene cloning and expression, purification and characterization of oncology, inflammation and infectious disease drug-target protein. Contribution to development of NMR-based methods and applications. Supervision of and participation in the co-crystallization of protein-ligand complexes and subsequent structural.

South San Francisco, California, US

NMR-based characterization of the variable domain of the Herceptin antibody. Expression and characterization of receptor fragments for NMR-based screening of small molecule solid and liquid tumor inhibitors.- Key contributions to multiple proprietary Ab fragment expression and isotopic labeling methods, many of which remain in practice at Genentech..

M.B.A., Technology Management

Ph.D., Chemistry

B.S., Chemistry